Clinical cancer genetics: Part I: Gastrointestinal

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 332-336

  Pollock, Jondavid ^a   Welsh, James S ^b,c  

^a WHEELING HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UW Cancer Center   (United States)

Author keywords

cancer genetics; cancer predisposition syndromes; familial cancer; gastrointestinal malignancies; hereditary cancer syndromes

Indexed keywords

ALPHA FETOPROTEIN; APC PROTEIN; BETA CATENIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; MISMATCH REPAIR PROTEIN PMS2; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN RET; SMAD4 PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UVOMORULIN;

BREAST CANCER; CANCER GENETICS; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CELL CYCLE; CELL PROLIFERATION; CHILDHOOD DISEASE; COLON RESECTION; COLONOSCOPY; DIGESTIVE SYSTEM CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL POLYPOSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC SCREENING; HAMARTOMA; HEPATOBLASTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIRSCHSPRUNG DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PELVIS CANCER; PEUTZ JEGHERS SYNDROME; PHENOTYPIC VARIATION; PROSTATE CANCER; RECTUM CANCER; RENDU OSLER WEBER DISEASE; REVIEW; RISK REDUCTION; STOMACH CANCER; THYMOMA; THYROID CANCER; TUMOR SUPPRESSOR GENE; TYLOSIS;

ADENOMATOUS POLYPOSIS COLI; CLINICAL MEDICINE; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INTESTINAL POLYPOSIS; NEOPLASMS, SECOND PRIMARY; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS; PEUTZ-JEGHERS SYNDROME; PREVALENCE; RADIOTHERAPY; STOMACH NEOPLASMS;

EID: 79958277867     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181dea432     Document Type: Review

References (31)

1. Lynch HT, Snyder CL, Lynch JF. The explosion of hereditary cancer knowledge: benefiting from a family information service. Community Oncol. 2007;4:22-28.
2. Bruinooge SS. American Society of Clinical Oncology policy statement: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406. (Pubitemid 46908372)
3. Peltomäki P. Lynch syndrome genes. Fam Cancer. 2005;4:227-232. (Pubitemid 41242191)
4. Fostira F, Thodi G, Konstantopoulou I, et al. Hereditary cancer syndromes. J BUON. 2007;12(suppl 1):S13-S22. (Pubitemid 350200857)
5. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257. (Pubitemid 36859476)
6. Jensen KC, Mariappan MR, Putcha GV, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol. 2008;32:1029-1037.
7. Matthews KS, Estes JM, Conner MG, et al. Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol. 2008;111: 1161-1166. (Pubitemid 351620352)
8. Bullow S. Familial polyposis coli. Dan Med Bull. 1987;34:1-15.
9. Campos FG, Imperiale AR, Seid VE, et al. Rectal and pouch recurrences after surgical treatment for familial adenomatous polyposis. Gastrointest Surg. 2009;13:129-136.
10. Gleeson FC, Papachristou GI, Riegert-Johnson DL, et al. Progression to advanced neoplasia is infrequent in post colectomy familial adenomatous polyposis patients under endoscopic surveillance. Fam Cancer. 2009;8: 33-38.
11. Jetter JM, Kohlmann W, Gruber SB. Genetics of colorectal cancer. Oncology. 2006;20:269 -276; discussion 285-286, 288-289. (Pubitemid 46940205)
12. Giardiello FM, Brensinger JD, Tersmette AC. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447-1453. (Pubitemid 32198669)
13. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med. 1998;128:896-899. (Pubitemid 28289483)
14. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316:1511-1514. (Pubitemid 17076235)
15. Hahn SA, Schutte M, Hoque TM, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-354.
16. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100:1771-1779.
17. Zacharatou Jarlskog C, Paganetti H. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ and patient age. Int J Radiat Oncol Biol Phys. 2008;72:228-235.
18. Basu SK, Schwartz C, Fisher SG, et al. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008;72:34-40.
19. Bjerkehagen B, Smeland S, Walberg L, et al. Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol. 2008;47:1475-1482.
20. Kendal W, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J Clin Oncol. 2007;30:333-339. (Pubitemid 47356675)
21. Brenner DJ. Induced second cancers after prostate-cancer radiotherapy: no cause for concern? Int J Radiat Oncol Biol Phys. 2006;65:637-639. (Pubitemid 43795858)
22. Baxter N, Tepper J, Durham S, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology. 2005;128: 819-824. (Pubitemid 40523534)
23. Welsh JS, Wilkins KB, Green R, et al. Association between thymoma and second neoplasms. JAMA. 2000;83:1142-1143.
24. Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2007;102:483-493. (Pubitemid 46328161)
25. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001;344:1904-1909. (Pubitemid 32553359)
26. Figer A, Irmin L, Geva R, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer. 2001;84:478-481. (Pubitemid 32215873)
27. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21-33. (Pubitemid 43221612)
28. Rebours V, Boutron-Ruault MC, Schnee M, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103:111-119.
29. Greer JB, Whitcomb DC, Brand RE. Genetic predisposition to pancreatic cancer: a brief review. Am J Gastroenterol. 2007;102:2564-2569. (Pubitemid 47631781)
30. Goggin M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996; 56:5360-5364. (Pubitemid 27011364)
31. Chapman P. Melanoma vaccines. Sem Oncol. 2007;34:516-523. (Pubitemid 350236310)